Gottlieb Attacks Rx Rebates; Drug-Channel Middlemen Face 3rd Day Of Negative Press

FDA Commissioner Scott Gottlieb said Wednesday (March 7) that the "rigged" rebate system discourages the development of biosimilars, which marked the third straight day of negative press for pharmacy benefit managers. However, Gottlieb's comments seem to be aimed at PBM tactics in the commercial market, which is the regulatory domain of agencies outside HHS, never mind FDA, that guard against anti-competitive business behavior, and PBM sources said there are FDA policies that do more to stifle the biosimilars market than...